[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

Recruiting

Phase 1

[Ac-225]-PSMA-62[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

Sponsor:

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

Code:

NCT06229366

Conditions

Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Oligometastatic Prostate Carcinoma

Hormone Sensitive Prostate Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

[Ac-225]-PSMA-62 (mCRPC)

[Ac-225]-PSMA-62 (OmHSPC)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company on 2025-04-18.